EZH2 and breast carcinoma: What’s more, EZH2 interacts directly with estrogen receptor and β-catenin through transactivation in its two N-terminal domains, thereby linking estrogen and Wnt signaling pathways to promote cell cycle progression and ER-positive breast cancer progression (Shi et al., 2007).